This 4 part-15 minute segmented vodcast/podcast will unite dermatology and allergy clinicians, who provide care for patients with moderate-to-severe atopic dermatitis (M-S AD). Patients with M-S AD often experience disease-related flare events, which can have a substantial impact on quality of life. However, advancements in systemic biologic agents have shown promise regarding their efficacy to the treatment and long-term management of flare events with minimal impact on patient safety. Expert faculty, Peter Lio, MD, FAAD; Mark Boguniewicz, MD; TJ Chao, MPAS, PA-C; and Victoria Lazareth, MA, MSN, NP-C, DCNP will discuss how to choose treatment and manage patients with M-S AD to prevent flare events, the impact that the disease and flare events have on quality of life including how to best assess patient symptoms, and strategies that ensure shared decision-making and collaboration with interdisciplinary teams to ensure optimal clinical outcomes for patients.
Speakers
Peter Lio, MD, FAAD
Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, IL
Peter Lio, MD, FAAD is a Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai, and a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University Feinberg School of Medicine. Dr. Lio received his medical degree from Harvard Medical School, completed his internship in Pediatrics at Boston Children’s Hospital, and his Dermatology training at Harvard where he served as Chief Resident in Dermatology. While at Harvard, he received formal training in acupuncture. Dr. Lio is the founding director of the Chicago Integrative Eczema Center and a founding partner of Medical Dermatology Associates of Chicago. He serves as a board member and scientific advisory committee member emeritus for the National Eczema Association. He is a member of the American Academy of Dermatology’s Atopic Dermatitis Expert Resource Group and a founding faculty member of the Integrative Dermatology Certificate Program. He has over 300 publications and 3 textbooks.
Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology,
Department of Pediatrics,
National Jewish Health and
University of Colorado School of Medicine
Denver, CO
Mark Boguniewicz, MD is Tenured Professor in the Division of Allergy-Immunology, Department of Pediatrics, at National Jewish Health and University of Colorado School of Medicine. He is a Fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI) and also of the American College of Allergy, Asthma, and Immunology (ACAAI). He has served on the editorial board of Journal of Allergy and Clinical Immunology: In Practice and on the Joint Taskforce on Topical Calcineurin Inhibitors of the AAAAI and ACAAI and was co-chair of the treatment section of the European Academy of Allergology and Clinical Immunology/AAAAI/PRACTALL Consensus Group for atopic dermatitis. He has served on the Joint Task Force of the AAAAI/ACAAI for the 2004 and 2012 Practice Parameter for Atopic Dermatitis and the 2023 Guidelines update. He co-chaired the Expert Panel on Management of Moderate-to- Severe Atopic Dermatitis and chaired the Atopic Dermatitis Yardstick and Update.
Dr. Boguniewicz’s research focuses on immunopathogenesis and new treatments for atopic dermatitis. He is an investigator of the NIH Atopic Dermatitis Research Network. He has lectured at many national and international meetings and has over 500 peer- reviewed articles, reviews, chapters and abstracts published. He is the recipient of the 1998-1999, 2010-2011, 2011-2012, 2012-2013, 2015-2017, 2017-2019, 2018-2020, 2021-2023 Pediatric Allergy-Immunology Fellows Outstanding Teacher Award, the 2002 Faculty Clinician of the Year Award, the 2006 AAAAI’s Richard S. Farr Memorial Lectureship, the 2020 AAAAI’s Bruton Lecture and has been selected for Best Doctors in America since 2003, as well as America’s Top Doctors and America’s Best Physicians 2023. He is also the recipient of the 2013 AAAAI Distinguished Clinician Award and the 2023 AAAAI Foundation and Donald Y.M. Leung, MD PhD FAAAI-JACI Editors Lectureship.
T.J. Chao, MPAS, PA-C
Physician Assistant
Atlanta North Dermatology
Woodstock, GA
T.J. Chao, MPAS, PA-C is a Certified Physician Assistant with over 23 years of Dermatology experience and 26 years of health care experience. T.J. graduated magna cum laude from the University of Florida in 1997 with a bachelor’s degrees in microbiology and nursing. He worked for three years in emergency and critical care medicine as a registered nurse. T.J. went on to earn a master’s degree in the Physician Assistant Program at the University of Florida, graduating at the top of his class in 2000.
T.J. Chao has practiced as a Dermatology Physician Assistant in the metro-Atlanta area since 2000. He is a national key opinion leader in the use of Biologics, and he has published numerous, articles on Biologics in Dermatology specific journals, including JDD, Cutis, JDPA and JAAPA. He frequently gives lectures at regional and national medical conferences on Biologics, small molecules and other Dermatology related subjects. TJ Chao also worked for Abbott Laboratories in 2005-2006 as an Immunology Specialist where he helped launch Humira into the Dermatology space.
T.J. has served as a Trustee and a three term President of the Georgia Dermatology Physician Assistants. TJ is an advisory board member and faculty board member for the Dermatology Education Foundation. He is also a member of the Society of Dermatology Physician Assistants, American Academy of Physician Assistants and Georgia Association of Physician Assistants. TJ is fluent in Spanish.
Victoria Lazareth, MA, MMSN, NP-C, DCNP
Dermatology Nurse Practitioner
Contemporary Dermatology
Marston Mills, MA
Victoria Lazareth MA, MSN, NP-C, DCNP is a Board Certified Dermatology Nurse Practitioner who has provided patients with Dermatology care for over 20 years.
She is a lecturer for multiple professional organizations, a contributing author to a dermatology textbook, the published author of Dermatology articles a content editor for the JDNA and the JCAD, and currently serves on the DCNP Recertification Committee.
Victoria provides General Dermatology care on Cape Cod MA with a particular focus on psoriasis and atopic dermatitis and sub-specializes in Cutaneous Oncology and Dermatologic Surgery.
Accreditation and Disclosure Information
Target Audience
This activity is intended for dermatologists/allergists, along with NPs and PAs, who are involved in the care of patients with M-S AD in the U.S.
Educational Objectives
After completing this activity, the participant should be better able to:
- Accurately assess dermatology-specific quality of life factors when choosing and managing treatments throughout the progression of M-SAD to align with clinical guidelines
- Select appropriate treatments by considering distinctions among drug mechanisms of action (MOA), efficacy, and safety data of both approved options and emerging biologic agents for M-S AD
- Consistently apply shared decision-making in all patient discussions concerning treatment selection, modification, or intensification while accounting for quality of life through patient-reported outcome assessments
Program Agenda
Part 1: M-S AD Disease Burden, Disease Progression, and Treatment Challenges
Part 2: Current and Developing Systemic Agents for Treating M-S AD in Accordance with Clinical Guidelines
Part 3: Utilizing QOL and PRO Assessment to Enhance Clinical Outcomes in M-S AD Management
Part 4: Incorporating Shared Decision-Making in All Facets of Treatment Selection to Address QOL
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Physician Associate Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 21, 2024. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
This activity is supported by an educational grant from Lilly.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Peter Lio, MD, FAAD
Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director, Chicago Integrative Eczema Center
Chicago, IL
Peter Lio, MD, FAAD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Almirall, Alphyn Biologics, Amyris, Inc., Apogee Therapeutics, Arbonne, Arcutis, Inc., ASLAN Pharmaceuticals, Bodewell, Boston Skin Science LLC, Bristol Myers Squibb, Burt’s Bees, Castle Biosciences, Codex Labs, Concerto Biosciences, Dermavant Sciences, Inc., Dermira, DermVeda, Eli Lilly and Company, Galderma Laboratories, LP, Janssen Pharmaceuticals, Inc, Johnson & Johnson Consumer Products Company, Kimberly Clark, LEO Laboratories Ltd (LEO Pharma), Lipidor, L’Oreal USA Inc., Merck, Micreos Human Health B.V., Modernizing Medicine, MyOR Diagnostics Ltd, National Eczema Association, Regeneron, Sanofi US Services, Sibel Health, Skinfix, Inc., Sonica LLC, Suneco Technologies, Syncere Skin Systems, Theraplex, UCB, Unilever, Verdant Scientific Inc., Verrica Pharmaceuticals Inc, YobeeCare Inc.
Research Grant: AbbVie, AOBiome, LLC, Eczema Foundation (formerly La Fondation pour la Dermatite Atopique), National Eczema Association, Regeneron.
Speakers’ Bureau: AbbVie, Almirall, Arcutis Biotherapeutics, Eli Lilly and Company, Galderma USA, Hyphens Pharma, Incyte Corporation, La Roche-Posay Laboratorie Pharmaceutique, LEO Pharma, MyOR Diagnostics Ltd, Pfizer, Pierre Fabre Dermatologie, Regeneron, Verrica Pharmaceuticals Inc.
Stock Options: Boston Skin Science LLC, Codex Labs, Concerto Biosciences, DermVeda, LearnHealth/LearnSkin, Medable, Micreos Human Health B.V., Modernizing Medicine, Suneco Technologies, Syncere Skin Systems, Verdant Scientific Inc., YobeeCare Inc.
Other: National Eczema Association (Board of Directors), ParentMD (patent/royalties), Theraplex (patent/royalties).
Planner/Presenter
Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology,
Department of Pediatrics,
National Jewish Health and University of Colorado School of Medicine
Denver, CO
Mark Boguniewicz, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Amgen, ASLAN, Dermavant, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi Genzyme
Research Grant: Incyte, Regeneron, Sanofi Genzyme
Planner/Presenter
T.J. Chao, MPAS, PA-C
Physician Assistant
Atlanta North Dermatology
Woodstock, GA
T.J. Chao, MPAS, PA-C, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Eli Lilly, Regeneron, Sanofi Genzyme
Speakers’ Bureau: AbbVie, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi Genzyme
Planner/Presenter
Victoria Lazareth, MA, MSN, NP-C, DCNP
Dermatology Nurse Practitioner
Contemporary Dermatology
Marston Mills, MA
Victoria Lazareth, MA, MSN, NP-C, DCNP, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: MauiDerm NP/PA; Boehringer Ingelheim, Bristol Myers Squibb, Incyte
Speakers’ Bureau: MauiDerm NP/PA, AANP, DNA, NPACE
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
If you have questions regarding your certificate, please contact mvu@mlieducation.org. For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by an educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.
Resources
Dermatology Dialogues Slides
Dermatology Dialogues Transcript
Episode 2 Resource: Clinical Guidelines
Episode 2 Resource: Safety Quick Reference
Episode 2 Resource: Dosing Quick Reference
Episode 3 Resource: Patient Reported-Outcomes + Quality of Life Assessments
Episode 4 Resource: VIBE Framework handout